We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
30 Jan 2023 - 02 Feb 2023

Ultra-Low Dose Total Body PET/CT Effective for Evaluating Arthritis

By MedImaging International staff writers
Posted on 14 Oct 2022
Print article
Image: Systemic joint evaluation in AIA (and non-AIA) is feasible with TB PET/CT system and ultra-low-dose protocol (Photo courtesy of University of California–Davis)
Image: Systemic joint evaluation in AIA (and non-AIA) is feasible with TB PET/CT system and ultra-low-dose protocol (Photo courtesy of University of California–Davis)

Autoimmune inflammatory arthritides (AIA) - such as psoriatic arthritis and rheumatoid arthritis - are chronic, systemic conditions that cause joint inflammation, joint destruction and pain. A new first-in-human research has found that total body PET/CT scans can successfully visualize systemic joint involvement in patients with autoimmune arthritis. The total body PET/CT scans showed high agreement with standard joint-by-joint rheumatological evaluation and a moderate to strong correlation with rheumatological outcome measures.

To assess the performance of molecular imaging to evaluate AIA, researchers at the University of California-Davis (Davis, CA, USA) used an ultra-low dose 18F-FDG total-body PET/CT acquisition protocol to scan 30 participants (24 with AIA and six with osteoarthritis). Participants also underwent a joint-by-joint rheumatological evaluation. In total, 1,997 joints were evaluated. Total body PET/CT was successful in visualizing 18F-FDG uptake at joints throughout the entire body, including those of the hands and feet, without the need for custom positioning of the participants.

In the AIA cohort, there was concordance between total body PET qualitative assessments and joint-by-joint rheumatological evaluation for 69.9% of the participants. About 20% of the AIA group had joints that were deemed negative on rheumatological evaluation but were positive on PET/CT, and 10 percent were negative on PET/CT but positive on the rheumatological evaluation. For the osteoarthritis cohort, there was agreement in joint assessment among 91.1% of participants. In this group 8.8% of joints were deemed negative on rheumatological evaluation but were positive on PET/CT, and no joints were negative on PET/CT but positive on rheumatological exam.

“Currently, there are significant clinical challenges in managing AIA populations. For example, it is unclear which patients should receive which treatments, how exactly these treatments change the inflammatory status of different tissues or outcomes, and the impact the disease and treatments have on other organs of the body,” said Abhijit J. Chaudhari, PhD, professor of radiology at the University of California–Davis in Davis, California. “Systemic molecular imaging enabled by total body PET could provide currently unavailable, objective biomarkers that could help address these challenges.”

“Systemic evaluation of arthritic disease activity across all musculoskeletal tissues of the body may provide unique insights for assessing disease burden risk stratification, treatment selection, and monitoring on treatment response. The biomarkers imaged may also have clear potential to accelerate arthritic drug discovery and development,” noted Chaudhari. “In addition, the inflammatory arthritides assessed in the paper are part of a broad category of autoimmune disorders. This work may contribute to improved understanding of total-body impact of autoimmunity.”

Related Links:
University of California–Davis 

Gold Supplier
SBRT Phantom with Removable Spine
E2E SBRT Phantom with Removable Spine Model 036S-CVXX-xx
New
Digital Color Doppler Ultrasound
EC100A
New
Endoscopic Ultrasound Processor
EU-ME3
New
POC Ultrasound System
Acclarix AX3

Print article
CIRS -  MIRION

Channels

MRI

view channel
Image: BlueSeal magnet for helium-free MR operations (Photo courtesy of Philips)

Use of High-Temperature Superconductors to Make MR Imaging More Affordable, Accessible and Sustainable

A new research partnership focuses on the use of high-temperature superconductors to make MR imaging more affordable, accessible and sustainable in the future. Operating at higher temperatures and eliminating... Read more

Ultrasound

view channel
Image: A combination of ultrasound and nanobubbles allows cancerous tumors to be destroyed without surgery (Photo courtesy of Tel Aviv University)

Ultrasound Combined With Nanobubbles Enables Removal of Tumors Without Surgery

The prevalent method of cancer treatment is surgical removal of the tumor, in combination with complementary treatments such as chemotherapy and immunotherapy. Therapeutic ultrasound to destroy the cancerous... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.